Alexion to start Soliris in COVID-19 Phase II trial in next few days
By MYBRANDBOOK
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company.
Castañeda comments: “The source explained that the idea behind Soliris is that the drug impacts the complement system, which could help reduce organ damage in severe COVID-19 patients.”
When asked to comment, an Alexion spokesperson pointed Castañeda to a media release stating how the company is interested in the potential use of Soliris in COVID-19 due to preclinical rationale that suggests it could be used in a subset of patients who have coronaviral infection and severe pneumonia or acute respiratory distress syndrome. Alexion is providing Soliris for experimental emergency treatment for a small number of patients with COVID-19 infection and severe pneumonia, it states.
Soliris made $3.95bn in 2019, as per SEC filings. It was first approved by the US Food and Drug Administration (FDA) in May 2007 for the rare blood disease paroxysmal nocturnal hemoglobinuria and subsequently approved in haemolytic uremic syndrome and myasthenia gravis in September 2011 and October 2017, respectively.
Castañeda continues: “This planned COVID-19 Phase II study is on the heels of a ten-patient, single-site, proof-of-concept trial, which started ten days ago, and data is expected to be revealed sometime this week, the source noted. While he declined to detail the status of these ten patients, he noted the patients improved in general.”
GlobalData’s COVID-19 Intelligence Dashboard shows that there are 623 clinical trials across the globe that are either planned or ongoing.
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
Icons Of India : B.V.R. Subrahmanyam
A 1987 batch (Chhattisgarh cadre) Indian Administrative Service Office...
ICONS OF INDIA : SANJAY NAYAR
Sanjay Nayar is a senior finance professional in the Indian private in...
ICONS OF INDIA : RITESH AGARWAL
Ritesh Agarwal is an Indian billionaire entrepreneur and the founder a...
IFFCO - Indian Farmers Fertiliser Cooperative
IFFCO operates as a cooperative society owned and controlled by its fa...
GeM - Government e Marketplace
GeM is to facilitate the procurement of goods and services by various ...
UIDAI - Unique Identification Authority of India
UIDAI and the Aadhaar system represent a significant milestone in Indi...
Indian Tech Talent Excelling The Tech World - Thomas Kurian, CEO- Google Cloud
Thomas Kurian, the CEO of Google Cloud, has been instrumental in expan...
Indian Tech Talent Excelling The Tech World - AJAY BANGA, President - World Bank
Ajay Banga is an Indian-born American business executive who currently...
Indian Tech Talent Excelling The Tech World - ANJALI SUD, CEO – Tubi
Anjali Sud, the former CEO of Vimeo, now leads Tubi, Fox Corporation...